We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
STE Beats on Q1 Earnings and Revenues, Raises '26 Sales View
Read MoreHide Full Article
Key Takeaways
STE reported Q1 adjusted EPS of $2.34, up 15.3% year over year and above consensus estimate.
STE's revenues grew 8.6% to $1.39B, driven by gains across Healthcare, AST and Life Sciences segments.
STE raised FY26 revenue growth guidance to 8-9%, with adjusted EPS forecast of $9.90-$10.15.
STERIS plc (STE - Free Report) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.34, up 15.3% from the year-ago quarter’s figure. The figure surpassed the Zacks Consensus Estimate by 0.9%.
The adjustment excludes the impacts of certain non-recurring charges, such as the amortization of acquired intangible assets and acquisition and integration-related charges.
The company’s GAAP EPS was $1.79, up 27% from the year-ago level of $1.41.
Following the earnings announcement, STE stock remained unchanged in after-market trading yesterday.
STE’s Q1 Revenues in Detail
Revenues of $1.39 billion from continuing operations increased 8.6% year over year. The figure missed the Zacks Consensus Estimate by 2.4%.
Organic revenues at constant exchange rate or CER rose 8% year over year.
STE’s Quarterly Performance in Detail
The company operates under three segments — Healthcare, Applied Sterilization Technologies (“AST”) and Life Sciences.
Revenues at Healthcare rose 8% year over year to $974.7 million (up 8% on a CER organic basis). This reflected 5% growth in consumable revenues, a 13% rise in service revenues and a 6% improvement in capital equipment revenues. Our model expected Healthcare segment revenues to improve 5.2% in the fiscal first quarter.
Revenues from AST improved 13% to $281.2 million (up 10% on a CER organic basis). This performance reflected 12% growth in service revenues and a 46% increase in capital equipment revenues. Our model anticipated a 6.3% improvement in the segment’s quarterly revenues.
Revenues from the Life Sciences segment increased 5% to $135.2 million (up 4% year over year on a CER organic basis). This performance reflected 8% growth in consumable revenues, a 3% rise in service revenues and a 1% improvement in capital equipment revenues. Our model projected a year-over-year increase of 6% for the segment’s revenues.
Margins
The gross profit in the reported quarter was $628 million, up 9.7% from the prior-year level. The gross margin expanded 41 basis points (bps) year over year to 45.1% despite a 7.9% increase in the cost of revenues.
STERIS witnessed a 5.4% year-over-year rise in selling, general and administrative expenses. The figure amounted to $353.8 million. Research and development expenses rose 3.1% to $26.4 million. Adjusted operating expenses totaled $380.2 million, up 5.3% year over year. The adjusted operating margin expanded 131 bps to 17.8%.
Financial Details
STERIS exited the first quarter of fiscal 2026 with cash and cash equivalents of $279.7 million compared with $171.7 million at the end of fiscal 2025.
Net cash flow from operating activities at the end of the fiscal first quarter was $420 million compared with $303.7 million in the year-ago period. Further, the company has a five-year annualized dividend growth rate of 9.03%.
Guidance
STERIS raised its fiscal 2026 revenue projection.
It now expects revenues from continuing operations to increase approximately 8-9%, up from the previous projection of 6-7%. The Zacks Consensus Estimate is pegged at $5.83 billion, implying 6.8% growth from fiscal 2025.
Constant currency organic revenues are expected to improve approximately 6-7%.
Adjusted EPS is expected to be in the range of $9.90-$10.15. The Zacks Consensus Estimate for the metric is pegged at $10.12.
Our Take
STERIS ended first-quarter fiscal 2026 on a solid note, wherein both earnings and revenues beat estimates. All business segments experienced growth during the quarter. The year-over-year top-line growth can be attributed to favorable foreign currency. Meanwhile, expansion of both margins, despite tariff headwinds, bodes well for the stock.
Furthermore, the raised sales guidance for fiscal 2026 looks encouraging.
STE’s Zacks Rank & Key Picks
STE currently carries a Zacks Rank #3 (Buy).
Some better-ranked stocks from the broader medical space are Boston Scientific (BSX - Free Report) , Cardinal Health (CAH - Free Report) and Cencora (COR - Free Report) .
Revenues of $5.06 billion topped the Zacks Consensus Estimate by 2.3%. BSX has a long-term earnings growth rate of 14% compared with the industry’s 14.2%.
Cardinal Health, carrying a Zacks Rank #2 at present, posted third-quarter fiscal 2025 adjusted EPS of $2.35, which exceeded the Zacks Consensus Estimate by 9.3%. Revenues of $54.88 billion missed the Zacks Consensus Estimate by 0.3%.
CAH has an estimated long-term earnings growth rate of 10.9% compared with the industry’s 9.9%.
Cencora currently carries a Zacks Rank #2. The Zacks Consensus Estimate for third-quarter fiscal 2025 adjusted EPS is currently pegged at $3.78 and the same for revenues is pinned at $80.33 billion.
Cencora has an estimated long-term growth rate of 12.8%. COR’s earnings yield of 5.4% compares favorably with the industry’s 4.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
STE Beats on Q1 Earnings and Revenues, Raises '26 Sales View
Key Takeaways
STERIS plc (STE - Free Report) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.34, up 15.3% from the year-ago quarter’s figure. The figure surpassed the Zacks Consensus Estimate by 0.9%.
The adjustment excludes the impacts of certain non-recurring charges, such as the amortization of acquired intangible assets and acquisition and integration-related charges.
The company’s GAAP EPS was $1.79, up 27% from the year-ago level of $1.41.
Following the earnings announcement, STE stock remained unchanged in after-market trading yesterday.
STE’s Q1 Revenues in Detail
Revenues of $1.39 billion from continuing operations increased 8.6% year over year. The figure missed the Zacks Consensus Estimate by 2.4%.
Organic revenues at constant exchange rate or CER rose 8% year over year.
STE’s Quarterly Performance in Detail
The company operates under three segments — Healthcare, Applied Sterilization Technologies (“AST”) and Life Sciences.
Revenues at Healthcare rose 8% year over year to $974.7 million (up 8% on a CER organic basis). This reflected 5% growth in consumable revenues, a 13% rise in service revenues and a 6% improvement in capital equipment revenues. Our model expected Healthcare segment revenues to improve 5.2% in the fiscal first quarter.
Revenues from AST improved 13% to $281.2 million (up 10% on a CER organic basis). This performance reflected 12% growth in service revenues and a 46% increase in capital equipment revenues. Our model anticipated a 6.3% improvement in the segment’s quarterly revenues.
Revenues from the Life Sciences segment increased 5% to $135.2 million (up 4% year over year on a CER organic basis). This performance reflected 8% growth in consumable revenues, a 3% rise in service revenues and a 1% improvement in capital equipment revenues. Our model projected a year-over-year increase of 6% for the segment’s revenues.
Margins
The gross profit in the reported quarter was $628 million, up 9.7% from the prior-year level. The gross margin expanded 41 basis points (bps) year over year to 45.1% despite a 7.9% increase in the cost of revenues.
STERIS witnessed a 5.4% year-over-year rise in selling, general and administrative expenses. The figure amounted to $353.8 million. Research and development expenses rose 3.1% to $26.4 million. Adjusted operating expenses totaled $380.2 million, up 5.3% year over year. The adjusted operating margin expanded 131 bps to 17.8%.
Financial Details
STERIS exited the first quarter of fiscal 2026 with cash and cash equivalents of $279.7 million compared with $171.7 million at the end of fiscal 2025.
STERIS plc Price, Consensus and EPS Surprise
STERIS plc price-consensus-eps-surprise-chart | STERIS plc Quote
Net cash flow from operating activities at the end of the fiscal first quarter was $420 million compared with $303.7 million in the year-ago period. Further, the company has a five-year annualized dividend growth rate of 9.03%.
Guidance
STERIS raised its fiscal 2026 revenue projection.
It now expects revenues from continuing operations to increase approximately 8-9%, up from the previous projection of 6-7%. The Zacks Consensus Estimate is pegged at $5.83 billion, implying 6.8% growth from fiscal 2025.
Constant currency organic revenues are expected to improve approximately 6-7%.
Adjusted EPS is expected to be in the range of $9.90-$10.15. The Zacks Consensus Estimate for the metric is pegged at $10.12.
Our Take
STERIS ended first-quarter fiscal 2026 on a solid note, wherein both earnings and revenues beat estimates. All business segments experienced growth during the quarter. The year-over-year top-line growth can be attributed to favorable foreign currency. Meanwhile, expansion of both margins, despite tariff headwinds, bodes well for the stock.
Furthermore, the raised sales guidance for fiscal 2026 looks encouraging.
STE’s Zacks Rank & Key Picks
STE currently carries a Zacks Rank #3 (Buy).
Some better-ranked stocks from the broader medical space are Boston Scientific (BSX - Free Report) , Cardinal Health (CAH - Free Report) and Cencora (COR - Free Report) .
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, reported a second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Revenues of $5.06 billion topped the Zacks Consensus Estimate by 2.3%. BSX has a long-term earnings growth rate of 14% compared with the industry’s 14.2%.
Cardinal Health, carrying a Zacks Rank #2 at present, posted third-quarter fiscal 2025 adjusted EPS of $2.35, which exceeded the Zacks Consensus Estimate by 9.3%. Revenues of $54.88 billion missed the Zacks Consensus Estimate by 0.3%.
CAH has an estimated long-term earnings growth rate of 10.9% compared with the industry’s 9.9%.
Cencora currently carries a Zacks Rank #2. The Zacks Consensus Estimate for third-quarter fiscal 2025 adjusted EPS is currently pegged at $3.78 and the same for revenues is pinned at $80.33 billion.
Cencora has an estimated long-term growth rate of 12.8%. COR’s earnings yield of 5.4% compares favorably with the industry’s 4.1%.